# Stryker Corporation (SYK)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/SYK/primer

## Business Model

---
ticker: SYK
step: 01
generated: 2026-05-12
source: quick-research
---

### Stryker Corporation (SYK) — Business Overview

#### Business Description
Stryker is one of the world's leading medical technology companies, with a market-leading position in robotic-assisted orthopedic surgery (Mako platform, 3,000+ installations + 2M+ procedures) plus broad MedSurg + Neurotechnology + Orthopaedics portfolios. CEO Kevin Lobo (since 2012). The $4.9B Inari Medical acquisition (2025) added vascular/VTE intervention as a new growth pillar. Mako spine + Mako shoulder launches in 2026 expand the robotic surgery franchise into adjacent specialties. In Q1 2026, Stryker reorganized: combining Mako + power tools + Ortho instruments into a new "Ortho Tech" business.

#### Revenue Model
- **MedSurg and Neurotechnology (~58% of revenue):** Instruments (power tools), Endoscopy, Medical (patient handling, EMS), Neurotechnology (neurosurgical, neurovascular, CMF)
- **Orthopaedics (~42%):** Joint replacement (knees, hips, shoulders), Trauma & Extremities, Spine, plus Mako enabling technology
- Recurring revenue from disposables + maintenance contracts + procedural consumables

#### Products & Services

##### Mako Robotic-Assisted Surgery
- **Mako SmartRobotics:** Multi-specialty robotic-arm assisted platform
- **Mako 4:** Latest generation (released 2024)
- **Mako RPS (Robotic Power System):** New handheld robotic system — limited market release 2026
- **Mako Total Knee, Partial Knee, Total Hip, Revision Hip**
- **Mako Spine (full launch 2026)**
- **Mako Shoulder (full launch 2026)**
- 3,000+ installations globally; 2M+ procedures cumulative

##### Orthopaedics
- **Joint Replacement:** Triathlon (knee), Tritanium (hip), MyKnee custom
- **Trauma & Extremities:** Pangea trauma system (global rollout), foot/ankle implants
- **Spine:** Tritanium spine system, navigation
- **Ortho Tech (reorganized 2026):** Combines Mako + power tools + Ortho instruments

##### MedSurg / Neurotechnology
- **Instruments:** Power tools (drills, saws, surgical drills) — largest installed base
- **Endoscopy:** 4K imaging, surgical visualization
- **Medical:** Stretchers, ICU beds, ambulance equipment, hospital communication, virtual care
- **Neurosurgical:** Neuroendoscopy, cranial implants
- **Neurovascular:** Trevo stent retrievers, aspiration systems for stroke
- **Inari Medical (acquired 2025 for $4.9B):** ClotTriever + FlowTriever for VTE
- **Craniomaxillofacial (CMF):** Cranial implants, plates, screws

#### Customer Base & Go-to-Market
- **Hospitals + ambulatory surgery centers:** Primary buyers
- **Orthopaedic surgeons:** Mako-trained network growing rapidly
- **Neurosurgeons + interventional radiologists:** Neurotechnology customers
- **EMS providers:** Medical products
- **Geographic mix:** ~75% US, ~25% International (growing internationally)
- **Channel:** Direct sales force + distributors internationally

#### Competitive Position
Stryker is #1 globally in orthopaedic robotic-assisted surgery (Mako vs Smith+Nephew CORI, J&J Velys, Zimmer ROSA). Moats: (1) Mako installed base of 3,000+ creates surgeon training network with switching costs, (2) deep relationships with US ortho practices, (3) Pangea trauma system gaining global share, (4) Inari VTE platform entering high-growth market. Competitors: J&J MedTech (orthopaedics + endoscopy), Medtronic (broad), Zimmer Biomet (orthopaedics), Smith+Nephew, Boston Scientific (in VTE).

#### Key Facts
- Founded: 1941 (Dr. Homer Stryker)
- Headquarters: Portage, MI
- Employees: ~52,000
- Exchange: NYSE
- Sector / Industry: Health Care / Medical Devices
- Market Cap: ~$155B (May 2026)
- CEO: Kevin Lobo (since 2012)
- Dividend: $3.40 annual ($0.85 quarterly)
- 30+ consecutive years of dividend growth
- Major recent M&A: Inari Medical $4.9B (2025)

## Financial Snapshot

---
ticker: SYK
step: 04
generated: 2026-05-12
source: quick-research
---

### Stryker Corporation (SYK) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | $20.5B | $22.6B | $25.1B | +11% |
| Adj. Gross Margin | 63% | 64% | 64% | flat |
| Adj. Operating Margin | 25% | 26% | 27% | +1pp |
| Adj. EPS | $10.95 | $12.20 | $13.63 | +12% |
| Free Cash Flow | $2.8B | $3.2B | $3.5B | +9% |

#### Segment Performance (FY2025)

| Segment | Revenue | YoY Growth |
|---------|---------|-----------|
| MedSurg & Neurotechnology | ~$14.5B | +10% |
| - Inari Medical (acquired 2025) | $300M+ | first partial year |
| - Instruments + Endoscopy | growing | |
| - Medical (patient handling, EMS) | strong | |
| Orthopaedics | ~$10.6B | +13% |
| - Knees (incl. Mako) | growing | |
| - Hips (incl. Mako Hip + Revision Hip) | growing | |
| - Trauma + Extremities | strong (Pangea rollout) | |

#### Q1 2026 Highlights

| Metric | Q1 2026 | YoY |
|--------|---------|-----|
| Sales | $5.7B | +2.6% (Cyberattack impact) |
| Adj. Gross Margin | 63.6% | -190bps (tariffs + lost manufacturing absorption) |
| Cyberattack revenue impact | -$310M | 3-week shutdown |
| Mako Q1 installations | best-ever | |

#### Mako Installations + Procedures

| Metric | Value |
|--------|-------|
| Cumulative Mako installations | 3,000+ globally |
| Cumulative Mako procedures | 2M+ (Q2 2025 milestone) |
| FY25 Mako growth | Record installations |
| FY26 launches | Mako Spine + Mako Shoulder (full launch) |
| Mako RPS handheld | Limited market release 2026 |

#### 2026 Guidance

| Metric | 2026 Guide |
|--------|------------|
| Organic Net Sales Growth | 8-9.5% |
| Adj. EPS | $14.90-15.10 |
| Tariff Headwind | ~$200M revenue |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$4.5B |
| Capital Expenditures | ~$0.8B |
| Free Cash Flow | $3.5B |
| Cash & Investments | ~$6B |
| Total Debt | ~$13B (post-Inari $4.9B) |
| Net Debt/EBITDA | ~1.7x |

#### Inari Medical Acquisition (2025)

| Metric | Value |
|--------|-------|
| Deal value | $4.9B |
| Products | ClotTriever, FlowTriever (VTE intervention) |
| 2026 Synergies | $100M+ |
| Strategic focus | High-growth VTE market |

#### Key Ratios (approximate, May 2026)
- P/E (forward): ~28x | EV/EBITDA: ~20x | Dividend Yield: ~0.95%
- ROIC: ~15%
- FCF Margin: ~14%

#### Growth Profile
FY25 revenue +11% to $25.1B; adj EPS +12% to $13.63. Q1 2026 sales only +2.6% due to $310M cyberattack revenue shortfall (3-week shutdown). Reaffirmed 2026 guidance at 8-9.5% organic + $14.90-15.10 EPS. Mako installations record; Mako Spine + Shoulder full launches in 2026. Inari VTE adding $100M+ synergies in 2026.

#### Forward Estimates
- **FY2026E Revenue:** ~$27B (+8-9%, includes tariff drag offset)
- **FY2026E Adj EPS:** $14.90-15.10 (mgmt)
- **FY2027E EPS:** ~$17 (+13%)
- **Long-term EPS growth target:** 10-15%
- **Mako Spine + Shoulder peak sales potential:** $500M+ annually

#### Capital Return
- Dividend $3.40 annual (~$1.3B paid)
- 30+ consecutive years of dividend growth
- Buybacks: ~$1B annual (moderated for Inari deleveraging)
- Total return: ~1% dividend + buybacks + 10-15% EPS growth

## Recent Catalysts

---
ticker: SYK
step: 12
generated: 2026-05-12
source: quick-research
---

### Stryker Corporation (SYK) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Mako Spine + Shoulder full launch 2026 — $500M+ peak potential** — Mako's 2026 expansion into spine and shoulder procedures could unlock $500M+ in annual revenue. Mako now has 3,000+ installations and 2M+ procedures cumulative. Adding two new specialties leverages the same trained-surgeon network + capital sales motion. The Mako moat compounds: each additional specialty makes the platform more valuable to a hospital.

2. **Mako RPS handheld + Q1 2026 record installations** — Mako RPS (Robotic Power System) is a new handheld robotic system that combines Mako's robotics + power tools. Limited market release 2026. Q1 2026 marked best-ever Mako installations globally + US. The "Ortho Tech" reorganization (Mako + power tools + Ortho instruments) simplifies the customer offering and accelerates innovation cadence.

3. **Inari Medical acquisition — VTE platform entry** — $4.9B Inari acquisition (2025) adds ClotTriever + FlowTriever for VTE (venous thromboembolism). VTE is a high-growth med tech market with strong clinical momentum. $100M+ synergies expected in 2026. Diversifies Stryker beyond orthopaedics into vascular intervention.

4. **30-year dividend growth track record + organic 8-9.5% guide** — Stryker has grown its dividend for 30+ consecutive years. 2026 organic sales guide of 8-9.5% is mid-to-high single digit growth even with $200M tariff headwind absorbed. Adj EPS guide $14.90-15.10 = double-digit EPS growth. Combined with 1% dividend + buybacks = ~14-16% total return potential.

#### Bear Case Risks

1. **Q1 2026 cyberattack — $310M revenue shortfall** — A March 2026 cyber incident shut down manufacturing for 3 weeks, costing $310M in lost revenue. Gross margin compressed 190bps from lost manufacturing absorption + tariffs. Bears worry that not all of this revenue comes back. Cyber risk is a recurring theme for med tech companies (Boeing, Solar Winds, MOVEit) and SYK's exposure is now visible.

2. **28x forward P/E — premium med-tech multiple** — Stryker trades at ~28x forward EPS vs. healthcare equipment sector ~22x. Premium reflects Mako quality, but Q1 2026 stock fell 6% on earnings — narrative is moving from "best-in-class compounder" to "execution check." Any further surgery slowdown or M&A integration stumble compresses multiple.

3. **Tariff headwind + margin pressure** — $200M revenue headwind in 2026 from tariffs. Adj gross margin compressed 190bps in Q1 26 from tariffs + cyber. If tariffs escalate or persist into 2027, margin recovery thesis slips. Bear case: tariffs become a permanent ~150bps drag.

4. **Inari integration risk** — $4.9B Inari deal increased interest expense significantly. VTE intervention market has competitive intensity (Boston Scientific Janus, Penumbra). If Inari integration disappoints or growth slows, the $100M+ 2026 synergy doesn't materialize and bear case develops.

#### Upcoming Events

- **Q2 2026 earnings (July 2026)** — Mako Spine + Shoulder launch tracking; cyber recovery; tariff impact
- **Q3 2026 earnings (October 2026)** — Mid-year guide reset
- **AAOS 2027 (March 2027)** — Annual ortho surgeon conference; Mako platform innovation showcases
- **Inari synergy realization** — Multi-quarter integration milestones
- **Tariff developments** — Ongoing tariff escalation/de-escalation impacts

#### Analyst Sentiment

Sell-side consensus is **Buy** with average price targets in the $440-470 range vs. recent ~$400 trading levels (~10-18% upside). Bulls cite Mako Spine + Shoulder catalysts, Inari VTE platform, 30-year dividend track record. Bears focus on 28x P/E, cyber + tariff impacts. Stock is one of the most consistent compounders in med tech but faces near-term turbulence.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/syk
- Full research API: GET /api/v1/research/SYK/memo
- Coverage universe: /stocks